Gunma, Japan

Hirohi Ohashi

This inventor holds 1 USPTO granted patent. Top assignee: Kirin Beer Kabushiki Kaisha. Active years: 2005.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Hirohi Ohashi. Retrieved from https://idiyas.com/inventor/hirohi-ohashi

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

Average Co-Inventor Count = 5.0

ph-index = 1


Company Filing History:


Years Active: 2005

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Hirohi Ohashi: Innovator in Urea Derivatives

Introduction

Hirohi Ohashi is a notable inventor based in Gunma, Japan. He has made significant contributions to the field of medicinal chemistry, particularly through his innovative work on urea derivatives. His research focuses on developing compounds that can effectively inhibit the CCR-3 receptor, which is implicated in various diseases.

Latest Patents

Hirohi Ohashi holds a patent for "Urea derivatives as inhibitors for CCR-3 receptor." This patent describes how urea and thiourea derivatives can inhibit the cell function of the chemokine receptor CCR-3. These compounds offer a promising approach for treating a range of diseases thought to be mediated by this receptor. The synthesis of these useful urea and thiourea derivatives can be achieved through both liquid and solid phase synthesis protocols. He has 1 patent to his name.

Career Highlights

Ohashi is currently associated with Kirin Beer Kabushiki Kaisha, where he continues to explore innovative solutions in his field. His work has garnered attention for its potential applications in therapeutic settings.

Collaborations

He has collaborated with notable colleagues, including Michael Hocker and Janak Padia, to advance his research and development efforts.

Conclusion

Hirohi Ohashi's contributions to the field of medicinal chemistry, particularly through his patent on urea derivatives, highlight his role as an innovator. His work has the potential to impact the treatment of diseases mediated by the CCR-3 receptor significantly.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…